March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Long-term Structural and Functional Outcomes of Ranibizumab Therapy for Neovascular Age-related Macular Degeneration
Author Affiliations & Notes
  • Angela L. Rees
    Medical Retina, Moorfields Eye Hospital, London, United Kingdom
  • Simona Degli Esposti
    Medical Retina, Moorfields Eye Hospital, London, United Kingdom
  • Oliver Comyn
    Medical Retina, Moorfields Eye Hospital, London, United Kingdom
  • Adnan Tufail
    Medical Retina, Moorfields Eye Hospital, London, United Kingdom
  • Praveen J. Patel
    Medical Retina, Moorfields Eye Hospital, London, United Kingdom
  • Footnotes
    Commercial Relationships  Angela L. Rees, None; Simona Degli Esposti, None; Oliver Comyn, None; Adnan Tufail, None; Praveen J. Patel, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 4400. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Angela L. Rees, Simona Degli Esposti, Oliver Comyn, Adnan Tufail, Praveen J. Patel; Long-term Structural and Functional Outcomes of Ranibizumab Therapy for Neovascular Age-related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2012;53(14):4400.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To report long-term visual acuity (VA) and spectral domain optical coherence tomography (SDOCT) morphology outcomes in a cohort of patients with neovascular age-related macular degeneration undergoing ranibizumab therapy

Methods: : A retrospective review of outcomes of therapy in consecutively treated eyes of patients with 24 months follow-up. Patients were treated with 3 loading dose injections with further treatment based on signals of disease activity. SDOCT images were read by experienced ophthalmologists with an assessment of abnormalities of retinal morphology at baseline, after 3 injections, after 12 and 24 months follow-up. VA outcomes were also recorded at these time points.

Results: : Of the 70 eyes of 70 consecutively treated patients identified with 24 months follow-up, 20% of patients gained 15 ETDRS letters or more after 3 injections, 31.4% after 12 months and 51.4% after 24 months. The proportion of patients who lost less than 15 letters of VA from baseline was 97.1% after 3 injections; 88.6% after 12 months and 88.6% after 24 months. The mean gain (+ SD) in VA from baseline was +6.2 + 10.9 ETDRS letters after 3 injections, +6.9 + 17.6 letters at 12 months and +11.2 + 20.1 letters at 24 months. Macular fluid was present on SDOCT in 93% of eyes at baseline, 66% after 3 injections, 69% at 12 months and 59% at 24 months.

Conclusions: : Ranibizumab therapy can lead to sustained improvements in visual acuity and OCT based macular morphology at 2 years in a "real-world" clinical cohort of patients with nAMD. Macular fluid persisted in over half of the cohort suggesting persistent or recurrent disease activity and the need for ongoing therapy.

Keywords: age-related macular degeneration • visual acuity • clinical (human) or epidemiologic studies: outcomes/complications 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×